PPARδ Agonist • NOT a SARM • GSK Abandoned

Cardarine (GW-501516): The Endurance Compound

📄 6 PubMed citations

Last updated: October 6, 2026

NOT a SARM — it's a PPARδ agonist. In mice it boosted running time 68% only when combined with exercise training; short human trials showed lipid changes; and serious toxicities in animal studies led GSK to stop development. Here's what the research actually shows.

🧪 Buy Cardarine at Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items
2.5–10mg
Daily Doses Tested in Human Trials
(Olson 2012 — not a recommendation)
68%
Longer Running Time
(Mice, Drug + Exercise Training Only)
12wk
Human Lipid Trial Length
(Olson 2012, n=268)

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →
⚠️ Regulatory Status & Safety Warning

Cardarine is NOT a SARM and NOT FDA approved. It's a PPARδ agonist developed for metabolic disorders. GlaxoSmithKline stopped development after serious toxicities were discovered in pre-clinical animal studies (WADA alert (March 2013), as republished by FINA/World Aquatics); GSK withdrew its FDA application in 2009 (GSK statement to The Conversation, 2013). Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013). No safe dose has been established.

All SARMs and this compound are banned by WADA in competitive sport. This page is for educational purposes only.

NOT FDA APPROVED WADA BANNED CANCER CONCERN

How Cardarine Works

Completely different from SARMs. Cardarine activates PPARδ (peroxisome proliferator-activated receptor delta) and is highly selective for it — more than 1,000-fold over the other PPAR subtypes on the human receptor (Oliver et al., Proc Natl Acad Sci USA 2001; PMID 11309497).

🎯
PPARδ Receptor Activation

Activating PPARδ switches on muscle genes for fatty acid uptake and oxidation. In a 2-week human study, 10 mg/day raised muscle CPT1b expression and the share of meal fat burned for energy (Risérus et al., Diabetes 2008; PMID 18024853).

🏃
68% Endurance Gain — Only With Training (Mice)

In sedentary mice, 4 weeks of GW501516 alone changed muscle gene expression but did not improve treadmill endurance. Paired with 4 weeks of exercise training, it increased running time by 68% and distance by 70% versus trained mice given vehicle (Narkar et al., Cell 2008; PMID 18674809). The AMPK activator AICAR, not GW501516, was the drug that raised endurance without exercise in that study. Mice engineered to express an activated form of PPARδ in muscle had more type I (oxidative) fibers and ran much farther (Wang et al., PLoS Biol 2004; PMID 15328533).

🫀
Lipid Profile Improvement

In a 12-week trial of 268 people with low HDL, 2.5–10 mg/day raised HDL cholesterol by up to 16.9% and lowered LDL cholesterol (by up to 7.3%) and triglycerides (by up to 16.9%) (Olson et al., Arterioscler Thromb Vasc Biol 2012; PMID 22814748). In a 2-week study in 6 moderately overweight men, 10 mg/day lowered triglycerides 30% and LDL 23%, with HDL unchanged (Risérus et al., Diabetes 2008; PMID 18024853). It was developed for dyslipidemia and metabolic syndrome.

⚠️
Cancer Concern (GSK Abandoned)

GSK stopped development after serious toxicities appeared in pre-clinical studies (WADA alert (March 2013), as republished by FINA/World Aquatics). Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013). The published human trials lasted 2–12 weeks and were not designed to detect cancer risk; there is no long-term human safety data.

What the Research Shows

Data context: The endurance data come from mice. The human data are small lipid trials lasting 2–12 weeks at 2.5–10 mg/day; they were not designed to detect cancer risk. Serious toxicities in animal studies ended the program.

Running Time: +68% (Mice, GW501516 + 4 Weeks Training vs Trained Controls)
No endurance gain from the drug alone in sedentary mice (Narkar et al., Cell 2008; PMID 18674809)
Triglycerides: up to −16.9% (Humans, 12 Weeks)
268 people with low HDL, 2.5–10 mg/day (Olson et al., Arterioscler Thromb Vasc Biol 2012; PMID 22814748)
HDL Cholesterol: up to +16.9% (Humans, 12 Weeks, 10 mg)
HDL was higher than placebo in a 2-week study of healthy volunteers (Sprecher et al., Arterioscler Thromb Vasc Biol 2007; PMID 17110604), but was unchanged in a 2-week study of overweight men (Risérus et al., Diabetes 2008; PMID 18024853)

Side Effects & Risks

⚠️ Cancer Risk
  • Serious toxicities in pre-clinical studies ended development
  • Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013)
  • No safe dose established
  • Human trials lasted only 2–12 weeks — too short to assess cancer risk
  • Unknown risk in people
Other Considerations
  • Published human trials were small and short
  • Black-market products are unregulated

Study Citations

Endurance Study (Mice)
AMPK and PPARdelta agonists are exercise mimetics
Narkar et al., Cell 2008; PMID 18674809 — GW501516 alone did not improve endurance in sedentary mice; with 4 weeks of training it raised running time 68% vs trained controls
Endurance Study (Transgenic Mice)
Regulation of muscle fiber type and running endurance by PPARdelta
Wang et al., PLoS Biol 2004; PMID 15328533 — mice expressing activated PPARδ in muscle
Human Lipid Trial (12 Weeks)
Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome
Olson et al., Arterioscler Thromb Vasc Biol 2012; PMID 22814748 — 2.5, 5 or 10 mg/day vs placebo, n=268
Human Metabolic Study (2 Weeks)
Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men
Risérus et al., Diabetes 2008; PMID 18024853 — 10 mg/day, 6 subjects per group
First-in-Human Study (2 Weeks)
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist
Sprecher et al., Arterioscler Thromb Vasc Biol 2007; PMID 17110604 — 2.5 or 10 mg/day in healthy volunteers
Discovery & Selectivity
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
Oliver et al., Proc Natl Acad Sci USA 2001; PMID 11309497
Rodent Tumour Findings
Anti-doping agency warns cheats on the health risks of “Endurobol”
The Conversation, March 2013 (article) — reports an increased risk of some forms of tumours in rats and mice given GW501516
Development Halted
WADA alert on GW501516: withdrawn from research after serious toxicities in pre-clinical studies

Key Takeaways

What We Know
  • NOT a SARM — PPARδ agonist with different mechanism
  • In mice, endurance rose 68% only with exercise training — not from the drug alone
  • Raised HDL and lowered triglycerides/LDL in 2–12 week human trials
  • GSK stopped development after serious pre-clinical toxicities
  • Rodent studies suggest an increased risk of some tumours in rats and mice (The Conversation, 2013)
  • WADA banned in sport
What We Don't Know
  • Cancer risk at human research doses
  • Long-term human safety data
  • Quality of research chemical supply
  • Whether it improves endurance in humans at all
  • Interaction with other compounds

Research Source

Swiss Chems is our affiliate vendor for research compounds.

🧬 Cardarine GW-501516 Buy from Swiss Chems — vendor-published COAs → Shop Now

Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).

Disclaimer

Educational purposes only. Not medical advice. Cardarine is NOT FDA approved. GSK stopped development after serious toxicities in pre-clinical studies. Banned by WADA. Consult healthcare provider. HighPeptides does not sell this compound.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.

Affiliate Vendor

Research-Grade Peptides

Swiss Chems publishes certificates of analysis for selected products (vendor-published, a claim to verify).

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.